JNP: The Journal for Nurse PractitionersSuboptimal Glycemic Management and Overtreatment in Older Adults with Diabetes and Frailty

🎓 Expert Commentary / Peer Perspective

This JNP review argues that many frail older adults remain exposed to intensive diabetes treatment strategies despite evidence supporting individualized glycemic goals and deprescribing approaches. The authors emphasize that hypoglycemia, falls, hospitalization, cognitive impairment, and treatment burden may outweigh the benefits of aggressive glucose control in this population.

Clinical Considerations

• Frailty, cognitive impairment, renal dysfunction, falls, and polypharmacy substantially increase hypoglycemia risk among older adults.
• Less stringent A1c targets around 7% to 8% may be appropriate when life expectancy, comorbidities, or frailty limit benefit from intensive treatment.
• Insulin and sulfonylureas remain major contributors to overtreatment because of their association with hypoglycemia.
• Structured deprescribing approaches such as the 4S Pathway may help simplify regimens while maintaining individualized glycemic control.
• GLP-1 receptor agonists may offer advantages in some older adults but require caution in thin or frail patients because of weight and muscle loss concerns.
• Continuous glucose monitoring may aid glycemic management while helping reduce hypoglycemia exposure during treatment deintensification.

Practice Applications

• Recognize overtreatment as a potential cause of falls, hospitalization, and hypoglycemia.
• Individualize glycemic goals according to frailty, life expectancy, and comorbidity burden.
• Review insulin and sulfonylurea necessity during routine medication reconciliation.
• Engage patients in shared decision-making regarding relaxed glycemic targets.
• Consider structured deprescribing frameworks when treatment risks exceed expected benefits.
• Monitor weight, functional status, fall risk, and hypoglycemia alongside A1c values.